Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Found this on MSN:

Immunomedics Patents `Immuno-Pet' Diagnostic Imaging Technology

February 25, 2000 08:29 AM
MORRIS PLAINS, N.J., Feb. 25 /PRNewswire/ -- Immunomedics, Inc. IMMU announced today that the U.S. Patent and Trademark Office has allowed a patent covering positron emission tomography (PET) with gallium-68 (Ga-68) chelates.
According to Dr. David M. Goldenberg, Chairman and CEO of the Company, "Immunomedics' scientists have invented a method of delivering a PET imaging isotope, Ga-68, by a 2-step, pre-targeting method involving a bispecific fusion protein. The bispecific fusion protein first targets to the diseased site by binding to a specific antigen, followed by the injection of a second agent comprising the PET isotope, which then binds to the bispecific fusion protein localized at the diseased tissue," he explained.

Dr. Goldenberg further stated: "This new method potentially allows high ratios of the PET isotope to be targeted to the diseased tissues, such as cancers or infections, as compared to normal, adjacent tissues."

"We believe this method couples the specificity of antibodies with the high sensitivity of PET imaging, thus creating a new imaging modality of `Immuno-PET,'" he remarked.

"We are very committed to protecting and defending our intellectual property, which now comprises a portfolio of over 60 issued U.S. and 192 issued foreign patents, with over 167 applications pending worldwide," Dr. Goldenberg concluded.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. The Company's first product, CEA- Scan(R) for the detection of colorectal cancer, is being marketed in the United States and Europe (approved in Canada). The Company's second diagnostic imaging product, LeukoScan(R), is being marketed in Europe for the diagnosis of osteomyelitis (bone infection). Immunomedics also has several other diagnostic imaging products and three therapeutic products in clinical trials.

This release, in addition to historical information, contains forward- looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company's Quarterly Report on Form 10-Q for the year ended December 31, 1999.

Company Contact: Cynthia L. Sullivan, Executive Vice President, (973) 605-8200, extension 109. Visit our web site at

SOURCE Immunomedics, Inc.


Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.